Oxford (OXFD) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oxford Immunotec Reports Second Quarter 2015 Financial Results
August 4, 2015 7:01 AM EDTSecond quarter revenue of $14.3 million increased 29% on a constant currency basis compared to prior year period Gross margin improved by 522 basis points compared to prior year period Received CE Mark for T-SPOT®.CMV and began enrolling patients in REACT Trial Signed exclusive licensing agreement with IDIBELL for B Cell measurement technology in July
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the... More
